Impaired VEGF-induced extravasation of Evans blue and FITC-dextran in TSAd-deficient mice. (A) Systemic (i.v.) administration of Evans blue in WT and tsad^−/− mice was followed 2 h later by intradermal injection of vehicle or VEGF (100 ng) on the back. Evans blue dye leakage in dorsal skin was assessed after 30 min. Representative images of three independent experiments using two to four mice/genotype each time with similar result. Bar, 5 mm. (B) Quantification of extravasated Evans blue by formamide extraction from skin samples in A, corrected for tissue weight. n = 5 (WT) and 6 (tsad^−/−) mice/genotype from 2 independent experiments. *, P < 0.05; **, P < 0.01. (C) Basal extravasation of systemically delivered Evans blue in kidney, lung, and skin as quantified by formamide extraction. n = 3 mice/genotype. Experiment was performed once. (D) Intradermal injection of vehicle or VEGF in the ear was followed by systemic administration (i.v.) of 70-kD FITC-dextran and leakage was assessed 30 min later. Representative images of three separate experiments using three to four mice/genotype each time. Bar, 100 µm. (E) Quantification of FITC-dextran extravasation by determination of fluorescence in the tissues shown in C. n = 4 mice/genotype from 1 representative experiment.*, P < 0.05; **, P < 0.01.